Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13120647 | 0.91 | CDK2 (0.57) | ALDH1A1SMN1; SMN2CDK2GSK3BRAB9A | |
| SCHEMBL13288977 | 0.89 | CDK2 (0.47) | ALDH1A1SMN1; SMN2CDK2GSK3BKMT2A | |
| SCHEMBL13289069 | 0.89 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2CDK2GSK3BKMT2A | |
| SCHEMBL13288958 | 0.88 | GSK3B (0.46) | ALDH1A1SMN1; SMN2CDK2GSK3BRAB9A | |
| SCHEMBL13289010 | 0.88 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2CDK2GSK3BKMT2A | |
| SCHEMBL13288974 | 0.87 | CDK2 (0.52) | ALDH1A1CDK2GSK3BRAB9AKMT2A | |
| SCHEMBL13289430 | 0.86 | GSK3B (0.49) | CDK2GSK3BRAB9AKMT2AMEN1 | |
| SCHEMBL13288963 | 0.85 | CDK2 (0.46) | CDK2GSK3BKMT2AMEN1 | |
| SCHEMBL13289440 | 0.84 | CDK2 (0.51) | CDK2GSK3B | |
| SCHEMBL12954278 | 0.84 | CDK2 (0.52) | ALDH1A1CDK2GSK3BRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |